Myokardia Inc (MYOK) Insider Jake Bauer Sells 5,000 Shares

Myokardia Inc (NASDAQ:MYOK) insider Jake Bauer sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jake Bauer also recently made the following trade(s):

  • On Tuesday, January 2nd, Jake Bauer sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $42.89, for a total transaction of $214,450.00.

Shares of Myokardia Inc (NASDAQ MYOK) traded up $0.90 during mid-day trading on Wednesday, reaching $48.45. 404,609 shares of the company’s stock were exchanged, compared to its average volume of 479,864. Myokardia Inc has a twelve month low of $10.55 and a twelve month high of $49.55. The company has a market cap of $1,730.00 and a P/E ratio of -65.47.

Myokardia (NASDAQ:MYOK) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The business had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. During the same period in the prior year, the firm posted ($0.35) EPS. The firm’s quarterly revenue was up 58.6% compared to the same quarter last year. equities research analysts expect that Myokardia Inc will post -1.62 EPS for the current year.

Several research firms have recently commented on MYOK. Wedbush reissued an “outperform” rating and set a $51.00 target price on shares of Myokardia in a research report on Wednesday, September 20th. Credit Suisse Group reissued an “outperform” rating and set a $55.00 target price (up from $45.00) on shares of Myokardia in a research report on Tuesday, September 19th. Zacks Investment Research downgraded shares of Myokardia from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. BidaskClub raised shares of Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Finally, TheStreet downgraded shares of Myokardia from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Myokardia has an average rating of “Hold” and a consensus price target of $54.83.

A number of hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its position in shares of Myokardia by 2.5% during the 2nd quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 455 shares during the period. American International Group Inc. lifted its stake in shares of Myokardia by 18.8% during the 3rd quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 2,018 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Myokardia by 12.4% during the 3rd quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after buying an additional 2,299 shares in the last quarter. Nationwide Fund Advisors lifted its stake in shares of Myokardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 2,591 shares in the last quarter. Finally, Hershey Trust Co. lifted its stake in shares of Myokardia by 26.0% during the 3rd quarter. Hershey Trust Co. now owns 20,064 shares of the biotechnology company’s stock valued at $860,000 after buying an additional 4,145 shares in the last quarter. 63.61% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/10/myokardia-inc-myok-insider-jake-bauer-sells-5000-shares.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit